Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Sellas Life Sciences Group Inc

SLS ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$9.68

▼ -4.68%

Market Cap $1.95B · Vol 1.58M

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$1.95B

Small Cap

Div Yield

N/A

EPS Growth

+18.00%

YoY

RSI (14)

38.24

Momentum

Beta

2.71

vs Market

52W High

$15.87

39.00% below

52W Low

$1.39

596.40% above

Volume

1.58M

Avg 1.46M

P/B

8.14

Price-to-book

ROE

N/A

Return on equity

Free Float

99.08%

Public shares

Shariah Compliance8 STANDARDS

✗ Sellas Life Sciences Group Inc (SLS) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SLS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-16.12%

-21.36%

-5.93%

+95.56%

YTD

+156.76%

+406.81%

+897.84%

+11.39%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-26,863,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-54.95% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	8.14
P/FCF	N/A
EPS Growth	+18.00%
Outstanding Shares	201.95M

Technical Indicators

50-Day SMA	$12.16
200-Day SMA	$8.57
RSI (14)	38.24
Beta	2.71
52-Week High	$15.87
52-Week Low	$1.39

Volume Today	1.58M
Avg Daily Volume (30D)	1.46M
Relative Volume	1.08x
Volatility (10D)	120.82
Volatility (30D)	92.27
Free Float	99.08%

Analyst Consensus

BUY

Current Price $9.68

Mean Target $32.50

52W Low$1.39 52W High$15.87

Current

Target

$1.39 $15.87

Current Analyst target

+235.74% upside potential · 2 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001T223C9

ISINUS81642T2096

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -2.98% ARGX.BR argenx SE +0.35% ARGX argenx SE -0.55% GMAB.CO Genmab A/S +3.27% GMAB Genmab A/S +1.01%

Company Profile

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.